Form 4: Aura Biosciences Director Sapna Srivastava Acquires Shares and Options

Director Sapna Srivastava acquired 10,500 shares of common stock and options for 14,500 shares of Aura Biosciences, Inc.

Summary

• On June 20, 2024, Sapna Srivastava, a director of Aura Biosciences, Inc., acquired 10,500 shares of common stock through a restricted stock unit (RSU) award.
• These RSUs will vest fully on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service.
• Srivastava also acquired options to purchase 14,500 shares of common stock at an exercise price of $6.93.
• These options will vest and become exercisable on the earlier of June 20, 2025, or the next annual meeting of the Issuer's stockholders, contingent upon continued service.
• Following these transactions, Srivastava directly owns 10,500 shares of Aura Biosciences, Inc. common stock and options for 14,500 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects a standard insider transaction. The acquisition of shares and options by a director is generally viewed positively, but it's a routine event.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future prospects.
• The vesting conditions tied to continued service align the director's interests with those of the shareholders.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the director's continued service, suggesting an expectation of ongoing involvement with the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. These transactions can be viewed as a signal of management's confidence in the company's prospects.

Stakeholder Impact

• The acquisition of shares by a director could positively influence shareholder sentiment.
• The vesting conditions tied to continued service align the director's interests with those of the shareholders.

Key Dates